EGFR and glioblastoma: The emerging role of molecular diagnostics has identified distinct biomarkers that accurately correlate with prognosis, with glioblastoma being associated with IDH-wildtype status, EGFR amplification, TERT promoter mutation, and concurrent gain of chromosome 7 and loss of chromosome 10 [4].